Development and application of site mapping methods for the design of glycosaminoglycans

Glycobiology

Volumn 24, Issue 9, 2014, Pages 840-851

  Agostino, Mark ^a   Gandhi, Neha S ^a   Mancera, Ricardo L ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

glycosaminoglycans; interaction analysis; molecular docking; site mapping; virtual screening

Indexed keywords

AMYLOID PRECURSOR LIKE PROTEIN 1; AMYLOID PRECURSOR PROTEIN; COMPLEMENT COMPONENT C1Q; EPITOPE; FIBROBLAST GROWTH FACTOR; GLYCOSAMINOGLYCAN; GROWTH FACTOR; LIPOCORTIN 2; LIPOCORTIN 5; NK1 PROTEIN; RANTES; STROMAL CELL DERIVED FACTOR 1; THROMBIN; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR 1; GLUCOSAMINOGLYCANS; PROTEIN BINDING;

ARTICLE; AUTOMATION; BINDING SITE; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; EPITOPE MAPPING; FOOT AND MOUTH DISEASE VIRUS; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; STATIC ELECTRICITY; VALIDATION STUDY; VIRUS PARTICLE; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; CARBOHYDRATE ANALYSIS; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; BINDING SITES; CARBOHYDRATE SEQUENCE; FIBROBLAST GROWTH FACTOR 1; GLYCOSAMINOGLYCANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING;

EID: 84905496054     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu045     Document Type: Article

References (66)

1. Agostino M, Jene C, Boyle T, Ramsland PA, Yuriev E. 2009. Molecular docking of carbohydrate ligands to antibodies: Structural validation against crystal structures. J Chem Inf Model. 49:2749-2760.
2. Agostino M, Mancera RL, Ramsland PA, Yuriev E. 2013. AutoMap: A tool for analyzing protein-ligand interactions using multiple ligand binding modes. J Mol Graph Model. 40:80-90.
3. Agostino M, Ramsland PA, Yuriev E. 2012. Antibody recognition of cancerrelated gangliosides and their mimics investigated using in silico site mapping. PLoS ONE. 7:e35457.
4. Agostino M, Sandrin MS, Thompson PE, Ramsland PA, Yuriev E. 2011. Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. Biopolymers. 96:193-206.
5. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA. 2009. In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. Mol Immunol. 47:233-246.
6. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA. 2010. Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. Glycobiology. 20:724-735.
7. Agostino M, Yuriev E, Ramsland PA. 2011. A computational approach for exploring carbohydrate recognition by lectins in innate immunity. Front Immunol. 2:23.
8. Bitomsky W, Wade RC. 1999. Docking of glycosaminoglycans to heparinbinding proteins: Validation for aFGF, bFGF, and antithrombin and application to IL-8. J Am Chem Soc. 121:3004-3013.
9. Brenke R, Kozakov D, Chuang G-Y, Beglov D, Hall D, Landon MR, Mattos C, Vajda S. 2009. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics. 25:621-627.
10. Bytheway I, Cochran S. 2004. Validation of molecular docking calculations involving FGF-1 and FGF-2. J Med Chem. 47:1683-1693.
11. Canales A, Lozano R, Lopez-Mendez B, Angulo J, Ojeda R, Nieto PM, Martin-Lomas M, Gimenez-Gallego G, Jimenez-Barbero J. 2006. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue. FEBS J. 273:4716-4727.
12. Chalmers DK, Roberts BP. 2011. Silico-A Perl molecular modelling toolkit. Available from http://silico.sourceforge.net/, last accessed February 12, 2014.
13. Coombe DR, Stevenson SM, Kinnear BF, Gandhi NS, Mancera RL, Osmond RI, Kett WC. 2008. Platelet endothelial cell adhesion molecule (PECAM-1) and its interactions with glycosaminoglycans. 2. Biochemical analyses. Biochemistry. 47:4863-4875.
14. Corbeil CR, Englebienne P, Moitessier N. 2007. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J Chem Inf Model. 2007:435.
15. Costa MGS, Batista PR, Shida CS, Robert CH, Bisch PM, Pascutti PG. 2010. How does heparin prevent the pH inactivation of cathepsin B? Allosteric mechanism elucidated by docking and molecular dynamics. BMC Genomics. 11:S5.
16. DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA. 1998. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature. 393:812-817.
17. Feinberg H, Castelli R, Drickamer K, Seeberger PH, Weis WI. 2007. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J BiolChem. 282:4202-4209.
18. Feinberg H, Taylor ME, Razi H, McBride R, Knirel YA, Graham SA, Drickamer K,WeisWI. 2011. Structural basis for langerin recognition of diverse pathogen and mammalian glycans through a single binding site. J Mol Biol. 405: 1027-1039.
19. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinaÿ P, Petitou M, Choay J. 1990. Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res. 195:157-167.
20. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shaw DE, Shelley M., et al. 2004. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 47:1739-1749.
21. Gandhi NS, Coombe DR, Mancera RL. 2008. Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosarninoglycans: 1. Molecular modeling studies. Biochemistry. 47:4851-4862.
22. Gandhi NS, Freeman C, Parish CR, Mancera RL. 2012. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-beta-d-glucuronidase (heparanase). Glycobiology. 22:35-55.
23. Gandhi NS, Mancera RL. 2008. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des. 72:455-482.
24. Gandhi NS, Mancera RL. 2009. Free energy calculations of glycosaminoglycanprotein interactions. Glycobiology. 19:1103-1115.
25. Gandhi NS, Mancera RL. 2010a. Can current force fields reproduce ring puckering in 2-O-sulfo-α-L-iduronic acid? A molecular dynamics simulation study. Carbohydr Res. 345:689-695.
26. Gandhi NS, Mancera RL. 2010b. Heparin/heparan sulphate-based drugs. Drug Discov Today. 15:1058-1069.
27. Gandhi NS, Mancera RL. 2011. Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols. J Chem Inf Model. 51:335-358.
28. Gandhi NS, Mancera RL. 2012. Prediction of heparin binding sites in bone morphogenetic proteins (BMPs). BBA Proteins Proteomics. 51:1374-1381.
29. Halgren TA. 2009. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 49:377-389.
30. Hu Y-P, Zhong Y-Q, Chen Z-G, Chen C-Y, Shi Z, Zulueta MML, Ku C-C, Lee P-Y, Wang C-C, Hung S-C. 2012. Divergent synthesis of 48 heparan sulfatebased disaccharides and probing the specific sugar-fibroblast growth factor-1 interaction. J Am Chem Soc. 134:20722-20727.
31. Huey R, Morris GM, OIson AJ, Goodsell DS. 2007. A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 28:1145-1152.
32. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. 1997. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA. 94:14683-14688.
33. Jin L, Barran PE, Deakin JA, Lyon M, Uhrín D. 2005. Conformation of glycosaminoglycans by ion mobility mass spectrometry and molecular modelling. Phys Chem Phys. 7:3464-3471.
34. Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA. 2006. Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem. 281:35478-35486.
35. Krieger E, Geretti E, Brandner B, Goger B,Wells TN, Kungl AJ. 2004. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: Support from isothermal fluorescence titrations. Proteins. 54:768-775.
36. Lang PT, Brozell SR, Mukherjee S, Pettersen ET, Meng EC, Thomas V, Rizzo RC, Case DA, James TL, Kuntz ID. 2009. DOCK 6: Combining techniques to model RNA-small molecule complexes. RNA. 15:1219-1230.
37. McGann M. 2011. FRED pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 51:578-596.
38. McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK. 2003. Gaussian docking functions. Biopolymers. 68:76-90.
39. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem. 19:1639-1662.
40. Mulloy B, Forster MJ. 2008. Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: A computational survey of the 4-helix cytokines. Mol Simul. 34:481-489.
41. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E. 2007. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem. 282:10018-10027.
42. Musafia B, Senderowitz H. 2010. Biasing conformational ensembles towards bioactive-like conformers for ligand-based drug design. Expert Opin Drug Discov. 5:943-959.
43. Ng KK-S, Kolatkar AR, Park-Snyder S, Feinberg H, Clark DA, Drickamer K,Weis WI. 2002. Orientation of bound ligands in mannose-binding proteins: Implications for multivalent ligand recognition. J Biol Chem. 277:16088-16095.
44. Nieto L, Canales A, Gimenez-Gallego G, Nieto PM, Jimenez-Barbero J. 2011. Conformational selection of the AGA*IA(M) heparin pentasaccharide when bound to the fibroblast growth factor receptor. Chem Eur J. 17:11204-11209.
45. Norgan AP, Coffman PK, Kocher J-PA, Katzmann DJ, Sosa CP. 2011. Multilevel parallelization of AutoDock 4.2. J Cheminform. 3:12.
46. Ostrovksy O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D. 2002. Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem. 277:2444-2453.
47. Pichert A, Samsonov SA, Theisgen S, Thomas L, Baumann L, Schiller J, Beck-Sickinger AG, Huster D, Pisabarro MT. 2012. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology. 22:134-145.
48. Pogány P, Kovács A. 2009. Conformational properties of the disaccharide building units of hyaluronan. Carbohydr Res. 344:1745-1752.
49. Pye DA, Vivès RR, Hyde P, Gallagher JT. 2000. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: Differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology. 10:1183-1192.
50. Raghuraman A, Mosier PD, Desai UR. 2006. Finding a needle in a haystack: Development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).J MedChem. 49:3553-3562.
51. Samsonov SA, Pisabarro MT. 2013. Importance of IdoA and IdoA(2S) ring conformations in computational studies of glycosaminoglycan-protein interactions. Carbohyd Res. 381:133-137.
52. Samsonov SA, Teyra J, Pisabarro MT. 2011. Docking glycosaminoglycans to proteins: Analysis of solvent inclusion. J Comput AidedMol Des. 25:477-489.
53. Sapay N, Cabannes E, Petitou M, Imberty A. 2011. Molecular modeling of the interaction between heparan sulfate and cellular growth factors: Bringing pieces together. Glycobiology. 21:1181-1193.
54. Sattelle BM, Hansen SU, Gardiner J, Almond A. 2010. Free energy landscapes of iduronic acid and related monosaccharides. J AmChem Soc. 132:13132-13134.
55. Schrödinger LLC. 2011. Glide, Version 5.7. New York, NY.
56. Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, Roulin K, Harrenga A, Wells TN, Proudfoot AE. 2004. The X-ray structure of RANTES: Heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure. 12:2081-2093.
57. Sherman W, Day T, Jacobson MP, Freisner RA, Farid R. 2006. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 49:534-553.
58. Silipo A, Zhang Z, Cañada FJ, Molinaro A, Linhardt RJ, Jimenez-Barbero J. 2008. Conformational analysis of a dermatan sulfate-derived tetrasaccharide by NMR, molecular modeling, and residual dipolar couplings. ChemBioChem. 9:240-252.
59. Takaoka T, Mori K, Okimoto N, Neya S, Hoshino T. 2007. Prediction of the structure of complexes comprised of proteins and glycosaminoglycans using docking simulation and cluster analysis. J Chem Theory Comput. 3:2347-2356.
60. Taylor KR, Rudisill JA, Gallo RL. 2005. Structural and sequence motifs in dermatan sulfate promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity. J Biol Chem. 280:5300-5306.
61. Tessier MB, Grant OC, Heimburg-Molinaro J, Smith D, Jadey S, Gulick AM, Glushka J, Deutscher SL, Rittenhouse-Olson K, Woods RJ. 2012. Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11. PLoS ONE. 8:e54874.
62. Torrent M, Victoria Nogues M, Boix E. 2011. Eosinophil cationic protein (ECP) can bind heparin and other glycosaminoglycans through its Rnase active site. J Mol Recognit. 24:90-100.
63. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. 2003. Improved protein-ligand docking using GOLD. Proteins. 52:609-623.
64. Yuriev E, Agostino M, Farrugia W, Christiansen D, Sandrin MS, Ramsland PA. 2009. Structural biology of carbohydrate xenoantigens. Expert Opin Biol Ther. 9:1017-1029.
65. Yuriev E, Farrugia W, Scott AM, Ramsland PA. 2005. Three-dimensional structures of carbohydrate determinants of Lewis system antigens: Implications for effective antibody targeting of cancer. Immunol Cell Biol. 83:709-717.
66. Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, Hsu BT, Rees DC. 1991. Three-dimensional structures of acidic and basic fibroblast growth factors. Science. 251:90-93.